Obesity can upregulate inflammasome activity [30], and although data on body mass index were not presented for patients recruited to SAILS [11] it is possible there may be differences in obesity, and therefore plasma IL-18 concentration, between the trial populations that may have influenced the effect of statin therapy. The gene discussed is IL18; the disease is Obesity.